Kimberly-Clark
KMB
$99.09
+0.96%
Kimberly-Clark Corp. is a global consumer staples manufacturer whose portfolio spans personal care (Huggies diapers, Pull-Ups, Kotex, Depend), consumer tissue (Kleenex, Cottonelle, Scott), and a professional away-from-home safety and sanitation business, with roughly half of sales generated in North America and the balance spread across Europe, Asia, and Latin America. As one of the most recognized branded household and personal products companies in the world, Kimberly-Clark competes on scale, brand equity, and distribution reach against peers like Procter & Gamble and Unilever, though its growth profile is more mature and its portfolio more concentrated in tissue and hygiene. The dominant investor narrative today centers on the pending acquisition of Kenvue's consumer health portfolio, expected to close in the second half of calendar 2026, which would meaningfully reshape the company's growth and margin profile while introducing integration risk. At the same time, the stock has been under significant pressure, with a depressed valuation and a dividend yield near 4.9% drawing income-oriented investors even as analysts debate whether the deal and soft organic growth justify a re-rating.…
KMB
Kimberly-Clark
$99.09
Related headlines
Investment Opinion: Should I buy KMB Today?
The synthesized recommendation is a Hold, balancing the attractive dividend yield and discounted valuation against the significant operational and integration risks. The analyst consensus rating of 'buy' with a mean of 2.44 and an average target price of $118.07 implies 20.3% upside, but the wide target range of $90 to $162 and the lack of recent upgrades suggest caution. The core thesis is that the stock is inexpensive on forward earnings and offers a high yield, but the revenue decline and high leverage limit near-term upside until the Kenvue deal closes and integration progress becomes clearer.
Supporting evidence for a Hold includes the forward PE of 13.11x, which is near the low end of the historical range and represents a 20-30% discount to the consumer defensive sector, and the 4.94% dividend yield, which is well above the market average. However, revenue growth is negative at -13.99% year over year, and the payout ratio of 82.1% leaves little room for error. Free cash flow of $2.578 billion covers the dividend, but the current ratio of 0.745 and debt-to-equity of 4.86 highlight balance sheet stress. The implied upside to the analyst average target is 20.3%, but the low target of $90 is below the current price, reflecting the bear case.
The biggest risks that could invalidate the thesis are a breakdown below the 52-week low of $92.42, a dividend cut, or a major integration misstep with Kenvue. The rating would upgrade to Buy if the stock breaks above the $110-$115 resistance zone with improving revenue trends, or if the forward PE compresses below 12x while maintaining the dividend. It would downgrade to Sell if revenue declines accelerate beyond -15%, if the dividend is cut, or if the Kenvue deal fails to close or integrates poorly. Relative to its history and peers, the stock appears undervalued on forward earnings but fairly valued on a risk-adjusted basis given the operational challenges.
Sign up to view all
KMB 12-Month Price Forecast
The forward-looking view is neutral with medium confidence, as the stock's deep discount and high yield are offset by negative revenue growth and integration uncertainty. The base case (55% probability) targets $105-$120, assuming the Kenvue deal closes and revenue stabilizes, while the bull case (25%) and bear case (20%) represent the tails. Key factors include the forward PE of 13.11x, which is near the low end of the historical range, and the 4.94% dividend yield, which is well covered by free cash flow but leaves little room for error. I would upgrade to bullish if revenue growth turns positive and the stock reclaims the $110-$115 resistance zone, and downgrade to bearish if revenue declines accelerate or the dividend is cut.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Kimberly-Clark's 12-month outlook, with a consensus price target around $117.80 and implied upside of +18.9% versus the current price.
Average Target
$117.80
0 analysts
Implied Upside
+18.9%
vs. current price
Analyst Count
—
covering this stock
Price Range
$90 - $162
Analyst target range
Kimberly-Clark is covered by 15 analysts, with a consensus recommendation of "buy" and a recommendation mean of 2.44, which on a typical 1-5 scale (1=Strong Buy, 5=Sell) leans toward the lower end of the buy/hold spectrum, suggesting moderate bullishness rather than strong conviction. The average target price is $118.07, which implies approximately 20.3% upside from the current price of $98.15, a meaningful premium that suggests analysts see the recent selloff as overdone. However, the consensus is not uniformly bullish, as institutional ratings show a mix of Overweight, Equal Weight, Neutral, Hold, and Buy ratings from firms including Piper Sandler, Wells Fargo, UBS, Barclays, B of A Securities, and Deutsche Bank, with no recent upgrades or downgrades indicating a stable but cautious stance. The estimated EPS average of $8.99 for the forward period, with a tight range of $8.89 to $9.08, reflects high confidence in near-term earnings, and the estimated revenue average of $35.82 billion suggests analysts expect modest top-line stabilization. The target price range is extremely wide, from a low of $90.00 to a high of $162.00, a spread of 80% relative to the low end, which signals significant disagreement about the company's trajectory. The high target of $162.00 likely assumes successful integration of the Kenvue acquisition, margin expansion, and a re-rating toward historical valuation levels, while the low target of $90.00 prices in continued revenue declines, integration missteps, and potential dividend pressure. The wide spread, combined with the stock trading near its 52-week low, suggests high uncertainty and that the market is currently assigning more weight to the bear case than the bull case. The lack of recent rating changes indicates analysts are in a wait-and-see mode ahead of the Kenvue deal closing, and the consensus target may be slow to adjust if the fundamental picture deteriorates further.
Drowning in data?
Find the real signal!
Bulls vs Bears: KMB Investment Factors
The bear case currently has stronger evidence, driven by the severe revenue decline of 13.99% year over year, high leverage with a debt-to-equity ratio of 4.86, and negative technical momentum with the stock down 24.19% over the past year. However, the bull case rests on a deeply discounted forward PE of 13.11x, a 4.94% dividend yield, and analyst consensus target of $118.07 implying 20.3% upside, suggesting the pessimism may be overdone. The single most important tension is whether the Kenvue acquisition will successfully integrate and catalyze a re-rating, or whether it will exacerbate existing operational challenges and further pressure the dividend. If the deal closes smoothly and margins hold, the stock could re-rate toward its historical valuation; if integration stumbles, the stock could break below its 52-week low of $92.42.
Bullish
- Deeply discounted forward valuation: KMB trades at a forward PE of just 13.11x versus a trailing PE of 16.59x, implying the market expects forward EPS of $8.99, a massive jump from the trailing EPS of $0.06 which was distorted by one-time items. This forward multiple is near the low end of the stock's historical 12x-24x range and represents a 20-30% discount to the broader consumer defensive sector, which typically trades in the high teens to low twenties. Such a low multiple suggests the market is pricing in significant pessimism that may already be reflected in the price.
- Attractive dividend yield near 5%: The stock offers a dividend yield of 4.94%, well above the S&P 500 average and many consumer staples peers, backed by trailing free cash flow of $2.578 billion. The quarterly dividend of approximately $418 million is comfortably covered by operating cash flow, though the payout ratio of 82.1% leaves limited room for error. For income-focused investors, this yield provides a compelling total return proposition if the stock stabilizes.
- Analyst consensus sees 20% upside: With 15 analysts covering the stock, the consensus recommendation is 'buy' with a mean rating of 2.44, and the average target price of $118.07 implies 20.3% upside from the current price of $98.15. The high target of $162.00 suggests that if the Kenvue acquisition integrates successfully and margins expand, the stock could re-rate substantially. The tight EPS estimate range of $8.89 to $9.08 for the forward period indicates high confidence in near-term earnings stability.
- Profitability remains solid despite revenue decline: Q1 2026 net income was $665 million with a net margin of 15.97%, up from $499 million and 12.23% in Q4 2025, and gross margin expanded to 36.85% from 35.91% in the prior quarter. This margin expansion, driven by cost controls and favorable mix, demonstrates the company's ability to protect profitability even as revenue fell 13.99% year over year. Operating margin of 11.41% and consistent positive EPS of $2.00 in the latest quarter underscore the resilience of the business model.
Bearish
- Severe revenue decline and negative growth: Q1 2026 revenue fell 13.99% year over year to $4.163 billion from $4.84 billion, marking a significant step-down from the $4.84-$4.93 billion levels seen in early 2025. Quarterly revenue has hovered between $4.08 billion and $4.16 billion over the past four quarters, indicating persistent top-line weakness across the portfolio. This negative growth trajectory is a major red flag for a consumer staples company that typically offers stability.
- High leverage and weak liquidity: The debt-to-equity ratio of 4.86 is extremely high, and the current ratio of 0.745 indicates that current liabilities exceed current assets, meaning the company relies heavily on operating cash flow to meet near-term obligations. With a payout ratio of 82.1%, there is limited financial flexibility if earnings decline further or if the Kenvue integration requires additional investment. The heavy debt load also makes the company vulnerable to rising interest rates, as evidenced by $58 million in quarterly interest expense.
- Technical breakdown and negative momentum: The stock is down 24.19% over the past year and trades at just 13.6% of its 52-week range, with a relative strength versus the S&P 500 of -40.41%. The 1-month decline of 9.90% is far steeper than the 3-month (-4.05%) and 6-month (-0.70%) figures, indicating accelerating downside momentum and a fresh leg lower. With the stock within 6% of its 52-week low of $92.42, a breakdown below that level could trigger further selling.
- Integration risk from Kenvue acquisition: The pending acquisition of Kenvue's consumer health portfolio introduces significant integration risk, including potential cultural clashes, systems integration challenges, and the possibility of overpaying. Recent news highlights that the deal is nearing closing but with key risks still ahead, and Kenvue itself faces headwinds from product litigation and analyst downgrades. If integration missteps occur, they could pressure margins and distract management from the core business.
KMB Technical Analysis
Kimberly-Clark is in a clear intermediate downtrend, with the stock down 24.19% over the past year and trading at just 98.15, which represents only about 13.6% of its 52-week range of 92.42 to 129.87. That positioning near the bottom of the annual range signals persistent selling pressure rather than a healthy pullback, and the shares are now within roughly 6% of their 52-week low, a zone that historically attracts value buyers but also risks becoming a falling knife if fundamentals deteriorate further. The stock's relative strength versus the S&P 500 is deeply negative at -40.41% over one year, underscoring severe underperformance versus the broader market. Short-term momentum has deteriorated sharply, with the stock down 9.90% over the past month versus a 1.06% decline in SPY, producing a relative strength of -8.84% and suggesting accelerating downside momentum. The 3-month change of -4.05% and 6-month change of -0.70% reveal that the recent selloff is a fresh leg lower after a period of relative stabilization, and the fact that the 1-month decline is far steeper than the 3-month and 6-month figures points to a momentum breakdown rather than a gradual drift. The stock's beta of 0.273 indicates very low volatility relative to the market, meaning the recent decline is driven by stock-specific factors rather than broad market weakness, which is a more concerning signal for holders. Key technical support sits at the 52-week low of 92.42, and a breakdown below that level would likely trigger further selling and open the door to new lows, while resistance is established at the 52-week high of 129.87, with intermediate resistance likely forming around the 110-115 area where the stock repeatedly stalled in July and August. The maximum drawdown of -31.97% confirms the severity of the decline from prior highs, and with the stock trading below its recent consolidation range, a sustained recovery would require a decisive reclaim of the 105-110 zone to signal a trend change.
Beta
0.27
0.27x market volatility
Max Drawdown
-31.0%
Largest decline past year
52-Week Range
$92-$128
Price range past year
Annual Return
-22.6%
Cumulative gain past year
| Period | KMB Return | S&P 500 |
|---|---|---|
| 1m | -10.2% | -2.0% |
| 3m | -5.0% | +1.4% |
| 6m | +0.4% | +15.0% |
| 1y | -22.6% | +15.7% |
| ytd | -2.3% | +11.6% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
KMB Fundamental Analysis
Kimberly-Clark's revenue trajectory has turned negative, with the most recent quarter (Q1 2026, ended March 31, 2026) generating $4.163 billion in revenue, down 13.99% year over year from $4.84 billion in Q1 2025. This decline is part of a broader pattern: quarterly revenue has hovered between $4.08 billion and $4.16 billion over the past four quarters, well below the $4.84-$4.93 billion levels seen in early 2025, indicating a meaningful step-down in the top line. Segment data shows diapers at $1.696 billion and consumer tissue at $1.04 billion as the largest contributors, with feminine care at $451 million, adult care at $483 million, and away-from-home professional products at $460 million, but the overall revenue softness suggests volume and/or pricing pressure across the portfolio. The pending Kenvue consumer health acquisition is the key swing factor for the growth story, as it would add a new growth vector, but until it closes, the organic trend remains uninspiring. Profitability remains solid for a consumer staples company, with Q1 2026 net income of $665 million and a net margin of 15.97%, up from $499 million and 12.23% in Q4 2025. Gross margin came in at 36.85% in Q1 2026, slightly above the 35.91% in Q4 2025 and 35.71% in Q3 2025, suggesting modest margin expansion despite the revenue decline, likely driven by cost controls and favorable mix. Operating margin was 11.41% in Q1 2026, and the company remains consistently profitable with positive EPS of $2.00 in the latest quarter, though the trailing twelve-month EPS of $0.06 reflects significant one-time items and the impact of the revenue decline. The balance sheet carries meaningful leverage, with a debt-to-equity ratio of 4.86 and a current ratio of 0.745, indicating that current liabilities exceed current assets and that the company relies on operating cash flow to manage near-term obligations. Free cash flow on a trailing twelve-month basis is $2.578 billion, which comfortably covers the quarterly dividend of approximately $418 million, but the payout ratio of 82.1% leaves limited room for error if earnings decline further. Return on equity is exceptionally high at 134.6%, though this is inflated by the very low equity base resulting from years of share buybacks and leverage, while return on assets is a more modest 10.2%. The company generated $745 million in operating cash flow in Q1 2026 against $424 million in capital expenditures, yielding $321 million in free cash flow for the quarter, a level that is adequate but not robust relative to the dividend and debt service obligations.
Quarterly Revenue
$4.2B
2026-03
Revenue YoY Growth
-14.0%
YoY Comparison
Gross Margin
36.9%
Latest Quarter
Free Cash Flow
$2.6B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is KMB Overvalued?
Because Kimberly-Clark is profitable with positive net income, the PE ratio is the primary valuation metric, and the stock trades at a trailing PE of 16.59x versus a forward PE of 13.11x. The gap between trailing and forward PE implies the market expects meaningful earnings growth, with forward EPS estimates averaging $8.99 versus the trailing figure, though the very low trailing EPS of $0.06 makes the trailing PE less meaningful and suggests significant one-time charges or adjustments in the trailing period. The forward PE of 13.11x is the more relevant metric and indicates a relatively inexpensive valuation for a large-cap consumer staples name. On a price-to-sales basis, the stock trades at 1.95x, and its EV/EBITDA of 12.94x and EV/Sales of 2.32x provide additional context, with the EV/EBITDA multiple appearing elevated relative to the earnings-based PE due to the company's heavy debt load. Compared to the broader consumer defensive sector, which typically trades at PE multiples in the high teens to low twenties, Kimberly-Clark's forward PE of 13.11x represents a discount of roughly 20-30%, suggesting the market is pricing in slower growth or deal-related uncertainty. The price-to-book ratio of 22.37x is extremely high, reflecting the company's negative or minimal book equity from years of buybacks, and is not a useful valuation anchor in this case. Historically, Kimberly-Clark's PE ratio has ranged from around 12x to 24x over the past several years, with the current trailing PE of 16.59x sitting in the middle of that band, but the forward PE of 13.11x is near the low end of the historical range, implying the market is pricing in pessimistic expectations. The PS ratio of 1.95x is also near multi-year lows, compared to historical PS ratios that frequently exceeded 8-10x in prior periods, though those figures may be distorted by data methodology differences. Overall, the valuation appears inexpensive on forward earnings and sales, but the discount likely reflects legitimate concerns about revenue declines, integration risk from the Kenvue deal, and a high dividend payout ratio that limits financial flexibility.
PE
16.6x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 13x~28x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
12.9x
Enterprise Value Multiple
Investment Risk Disclosure
Kimberly-Clark faces significant financial and operational risks, primarily stemming from its high leverage and weak liquidity. The debt-to-equity ratio of 4.86 is exceptionally high for a consumer staples company, and the current ratio of 0.745 indicates that current liabilities exceed current assets, leaving little cushion for unexpected expenses. The payout ratio of 82.1% means that the dividend, while attractive at 4.94%, consumes the vast majority of earnings and leaves limited room for error if earnings decline further. Additionally, the 13.99% year-over-year revenue decline in Q1 2026 highlights the company's vulnerability to volume and pricing pressures across its portfolio, particularly in diapers and consumer tissue, which together account for over $2.7 billion in quarterly sales.
Market and competitive risks are also pronounced, given the stock's deep underperformance and the challenging industry backdrop. The stock's beta of 0.273 indicates very low volatility relative to the market, meaning the recent 24.19% decline is driven by stock-specific factors rather than broad market weakness, which is a more concerning signal for holders. The forward PE of 13.11x represents a discount to the consumer defensive sector, but this discount could persist or widen if revenue declines continue or if the Kenvue integration falters. Competitive pressures from larger peers like Procter & Gamble and Unilever, as well as private-label brands, could further erode market share. Recent news highlights integration risks from the Kenvue deal, and Kenvue itself faces product litigation and analyst downgrades, which could spill over to Kimberly-Clark.
In a worst-case scenario, a combination of continued revenue declines, integration missteps from the Kenvue acquisition, and a dividend cut could drive the stock down to its 52-week low of $92.42, representing a decline of approximately 5.8% from the current price of $98.15. If the bear case fully materializes, with the stock breaking below its 52-week low and approaching the analyst low target of $90.00, the downside could be around 8.3%. However, if the company faces a severe earnings miss or a dividend reduction, the stock could fall further, potentially to the $80-$85 range, implying a 13-18% decline. The maximum drawdown of -31.97% over the past year shows that such a scenario is not unprecedented, and investors should be prepared for significant volatility.
FAQ
The most severe risk is financial: the debt-to-equity ratio of 4.86 and current ratio of 0.745 indicate high leverage and weak liquidity, while the 82.1% payout ratio leaves little room for error. Second, operational risk from the 13.99% revenue decline and potential further market share losses to competitors like Procter & Gamble. Third, integration risk from the Kenvue acquisition, which could distract management and pressure margins if synergies are not realized. Fourth, market risk from the stock's negative momentum, with a 24.19% one-year decline and relative strength of -40.41% versus the S&P 500, which could continue if sentiment remains negative.
The 12-month forecast has three scenarios: a base case (55% probability) targeting $105-$120, assuming the Kenvue deal closes and revenue stabilizes; a bull case (25%) targeting $130-$162, driven by successful integration and margin expansion; and a bear case (20%) targeting $80-$92, if integration fails and revenue declines accelerate. The most likely scenario is the base case, with the key assumption that revenue declines moderate to low single digits and the dividend remains intact. The analyst average target of $118.07 aligns with the upper end of the base case, implying 20.3% upside from the current price of $98.15.
KMB appears undervalued on forward earnings, with a forward PE of 13.11x versus a trailing PE of 16.59x and a historical range of 12x-24x. The PS ratio of 1.95x is also near multi-year lows, and the EV/EBITDA of 12.94x is elevated due to the heavy debt load. Compared to the consumer defensive sector, which trades at high teens to low twenties PE, KMB is at a 20-30% discount. However, this discount reflects legitimate concerns about revenue declines and integration risk. The market is pricing in pessimistic expectations, and if the company can stabilize revenue and execute on the Kenvue deal, the multiple could expand toward the sector average.
From a risk/reward perspective, KMB offers a 20.3% upside to the analyst average target of $118.07, but the downside risk to the 52-week low of $92.42 is about 5.8%, and the bear case target of $90 implies 8.3% downside. The stock trades at a forward PE of 13.11x, which is cheap relative to the consumer defensive sector, and offers a 4.94% dividend yield. However, the 13.99% revenue decline and high debt-to-equity ratio of 4.86 are significant concerns. It could be a good buy for income-focused investors with a long horizon who believe in the Kenvue turnaround, but it is not suitable for those seeking growth or near-term capital appreciation.
KMB is more suitable for long-term investment, given its mature growth stage, low beta of 0.273, and high dividend yield of 4.94%. The stock is not a short-term trading vehicle due to its low volatility and the overhang of the Kenvue integration, which may take several quarters to play out. Income investors should consider a minimum holding period of 2-3 years to allow the acquisition to close and synergies to materialize. Short-term traders might find opportunities around the deal closing or earnings announcements, but the risk/reward is less favorable given the negative momentum and wide analyst dispersion.
